Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-8.20M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.20 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -90.11% |
| Return on Assets (Trailing 12 Months) | -84.53% |
| Current Ratio (Most Recent Fiscal Quarter) | 25.29 |
| Quick Ratio (Most Recent Fiscal Quarter) | 25.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.33 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.32 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.26 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 41.08M |
| Free Float | 7.97M |
| Market Capitalization | $43.14M |
| Average Volume (Last 20 Days) | 0.01M |
| Beta (Past 60 Months) | -1.12 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 80.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 28.40% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |